HC Wainwright Reiterates “Buy” Rating for Evaxion Biotech A/S (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $14.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 354.55% from the stock’s previous close.

Evaxion Biotech A/S Stock Up 8.8 %

Shares of EVAX stock traded up $0.25 on Thursday, hitting $3.08. 634,951 shares of the stock were exchanged, compared to its average volume of 257,270. The firm has a market capitalization of $17.19 million, a P/E ratio of -0.71 and a beta of -0.27. Evaxion Biotech A/S has a fifty-two week low of $2.26 and a fifty-two week high of $13.61. The business has a 50-day moving average of $2.99 and a 200 day moving average of $3.31. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its earnings results on Wednesday, August 14th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.14). The company had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.10 million. During the same period last year, the firm earned ($2.10) EPS. Equities analysts anticipate that Evaxion Biotech A/S will post -0.24 EPS for the current year.

Institutional Investors Weigh In On Evaxion Biotech A/S

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invst LLC bought a new position in shares of Evaxion Biotech A/S in the second quarter valued at $156,000. LM Advisors LLC acquired a new stake in Evaxion Biotech A/S in the fourth quarter valued at $231,000. Finally, Armistice Capital LLC grew its position in shares of Evaxion Biotech A/S by 6.8% in the 2nd quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock valued at $1,137,000 after acquiring an additional 25,000 shares during the period. Institutional investors own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.